Mottiwala Aziz — SEC Form 4 filings
SEC reporting owner CIK 1788542. 10 Form 4 filings on record with FilingPulse; latest filed 2026-07-24.
Transaction summary — filings shown
Covers all 10 filings on record, filed 2024-03-11 to 2026-07-24. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 8 legs across 4 filings — 45,887 shares, $2,310,024 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 20.
- Largest priced transaction: sale of 17,500 shares @ $43.76 ($765,800) in Tarsus Pharmaceuticals, Inc., filed 2025-06-11.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | Chief Commercial Officer | 9 | — | 8 legs · 45,887 sh · $2,310,024 | 18 |
| RxSight, Inc. (RXST) | President and CEO, Director | 1 | — | — | 2 |
Form 4 filings — Mottiwala Aziz
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-24 | 4 | RxSight, Inc. (RXST) | Grant/award (A): 2,312,138 (derivative) @ $0 · Grant/award (A): 571,286 (derivative) @ $0 | EDGAR |
| 2026-03-19 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 4,286 @ $69.42 · Sale (S): 4,330 @ $68.71 · Sale (S): 4,440 @ $67 | EDGAR |
| 2026-03-17 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Option exercise (M): 26,482 · Option exercise (M): 4,790 (derivative) @ $0 · Option exercise (M): 8,148 (derivative) @ $0 · Option exercise (M): 8,020 (derivative) @ $0 · Option exercise (M): 5,524 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Grant/award (A): 30,724 (derivative) @ $0 · Grant/award (A): 19,306 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 17,500 @ $43.76 | EDGAR |
| 2025-03-20 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 3,643 @ $46.29 · Sale (S): 3,557 @ $47.40 · Sale (S): 3,365 @ $50.11 | EDGAR |
| 2025-03-18 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Option exercise (M): 20,957 · Option exercise (M): 4,790 (derivative) @ $0 · Option exercise (M): 8,148 (derivative) @ $0 · Option exercise (M): 8,019 (derivative) @ $0 | EDGAR |
| 2025-03-07 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Grant/award (A): 33,691 (derivative) @ $0 · Grant/award (A): 22,098 (derivative) @ $0 | EDGAR |
| 2024-03-19 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Option exercise (M): 12,938 · Sale (S): 4,766 @ $30.60 · Option exercise (M): 4,790 (derivative) @ $0 · Option exercise (M): 8,148 (derivative) @ $0 | EDGAR |
| 2024-03-11 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Grant/award (A): 47,500 (derivative) @ $0 · Grant/award (A): 32,079 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1788542 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →